Vetmulin 125 mg/ml Concentrate for Oral Solution

Main information

  • Trade name:
  • Vetmulin 125 mg/ml Concentrate for Oral Solution
  • Pharmaceutical form:
  • Oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Vetmulin 125 mg/ml Concentrate for Oral Solution
    Greece
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Tiamulin
  • Therapeutic area:
  • Chicken, Pigs, Turkeys

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0202/001
  • Authorization date:
  • 25-11-2009
  • EU code:
  • FR/V/0202/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Vetmulin125mg/mlOralSolutionforuseindrinkingwaterforpigs(BE,BG,CZ,

EL,HU,IE,NL,PL,RO,UK,ES,IT,AT,DE,PT)

VetmulinVet,OralSolutionforuseindrinkingwaterforpigs(DK)

Vetmulin101.2mg/mlOralSolutionforuseindrinkingwaterforpigs(FR)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance125mgTiamulinhydrogenfumarate(equivalentto101.2mg

tiamulin

Excipients

Methylparahydroxybenzoate(E218):0.90mg

Propylparahydroxybenzoate(E216):0.10mg

Forafulllistofexcipients:seesection6.1

3. PHARMACEUTICALFORM

Oralsolutionforuseindrinkingwater

Clearcolourlesstoslightlyyellowliquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Pigs

4.2 Indicationsforuse(specifyingthetargetspecies)

Forthetreatmentofswinedysenterycausedbyorfurthercomplicatedbytiamulin-

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

susceptibleBrachyspirahyodysenteriae.

Treatmentofenzooticpneumoniaandthereductionoflesionscausedbytiamulin-

susceptibleMycoplasmahyopneumoniae

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

4.3 Contraindications

Donotuseinanimalswithknownhypersensitivitytotheactiveingredient.

Donotadministerproductscontainingmonensin,salinomycin,narasin,

maduramycinorotherionophoresduringorforatleastsevendaysbeforeorafter

treatmentwiththeproduct.Seealsosection5.1.and4.8.

4.4 Specialwarnings(foreachtargetspecies)

Theuptakeofmedicationbyanimalscanbealteredasaconsequenceofillness.

Incaseofinsufficientuptakeofwater,animalsshouldbetreatedparenterally.

4.5 Specialprecautionsforuse

4.5.1Specialprecautionsforuseinanimals

Useoftheproductshouldbebasedonsusceptibilitytestingandtakeinto

accountofficialandlocalantimicrobialpolicies

Strategictreatmentshouldbelimitedtoanimalswheretiamulinsusceptible

agentshavebeenisolatedintheherd.Longtermorrepeateduseshouldbe

avoidedbyimprovingmanagementpracticeandthoroughcleansingand

disinfection

Severegrowthdepressionordeathmayresultifanimalsreceiveproducts

containingmonensin,salinomycin,narasin,maduramycinorother

ionophoresduringorforatleastsevendaysbeforeoraftertreatmentwith

theproduct.Seealsosection4.3and4.8.

4.5.2Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Peoplewithknownhypersensitivitytotheactivesubstancemustnot

administertheveterinarymedicinalproduct.

Whenmixing,directcontactwiththeskinandmucousmembranesshouldbe

avoided.Accidentalingestionshouldbeavoided.Wearoveralls,safety

glasses,maskandimperviousgloveswhenhandlingormixingtheproduct.

Contaminatedclothingshouldberemovedandanysplashesontotheskin

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

shouldbewashedoffimmediately.Ifaccidentaleyecontactoccurs,

immediatelyrinsethoroughlywithwater.Seekmedicaladviceifirritation

persists.

Washhandsafteruse.

4.6 Adversereactions(frequencyandseriousness)

Inrarecases,hypersensitivitytotiamulinfollowingoraladministrationisreportedin

termsofcutaneousandgenitalerythemaandpruritus.Theadversereactionsare

oftenmildandtransientbutinveryrarecasesmaybeserious.Ifthesetypicalside

effectsoccur,stoptreatmentimmediatelyandcleananimalsandpenswithwater.

Normally,theanimalsrecoverfastthereafter.Symptomatictreatmentsuchas

electrolytetherapyandananti-inflammatorytherapymaybeuseful.

4.7 Useduringpregnancy,lactationorlay

Theproductcanbeusedduringpregnancyandlactation.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Animalsshouldnotreceiveproductscontainingmonensin,salinomycin,narasin,

maduramycinorotherionophoresduringorforatleastsevendaysbeforeorafter

treatmentwiththeproduct.Severegrowthdepression,paralysisordeathmayresult.

Tiamulinmaylessentheantibacterialactivityofß-lactamantibioticswhoseactionis

dependentonbacterialgrowth.

Crossresistancemayoccurbetweenothermembersofmacrolidesorlincosamide

antibiotics.Resistancetotheactivesubstanceandcrossresistanceshouldbe

consideredbeforetheproductisused.

Seealsosection4.3and4.5.1.

4.9 Amount(s)tobeadministeredandadministrationroute

Fororaladministrationthroughthedrinkingwater

Swinedysentery

8.8mgtiamulinhydrogenfumarateperkgbodyweightperday(equivalentto

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

7mlproductper100kgbodyweightperday)for5consecutivedays.

Enzooticpneumonia

15-20mgtiamulinhydrogenfumarateperkgbodyweightperday(equivalentto12 –

16mlproductper100kgbodyweightperday)for5days.

Administration:

Theuptakeofmedicatedwaterdependsontheactualbodyweight,thewater

consumption,theclinicalconditionoftheanimals,theenvironment,theageandthe

kindoffeedprovided.Inordertoobtainthecorrectdosage,theconcentrationof

tiamulinshouldbecalculated,asfollows:

.....mlVetmulin125mg/ml

oralsolutionforusein

drinkingwaterperkgbody

weightandday

x Averagebody

weight(kg)

=....mlVetmulin125mg/ml

oralsolutionforusein

drinkingwaterperlitreof

drinkingwater

Averagedailywaterintake(l/animal)

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

Therequireddosesshouldbemeasuredbysuitablycalibratedmeasuring

equipment.Medicatedwatershouldberefreshedevery24hours.Theuptakeof

consistentamountsofdrinkingwatershouldbeensuredbysufficientdrinking

facilities.

Toavoidformationofresistancebyconsumptionoftiamulininsubtherapeutic

doses,thewateringequipmenthastobecleanedadequatelyattheendof

treatment.

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

4.10 Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Asingleoraldoseof100mg/kgBWcausedhyperpnoeaandabdominalcomplaints

inpigs.Atadoseof150mg/kgtheonlyeffectsonthecentralnervoussystemwas

lethargy.Adoseof55mg/kgduring14dayscausedincreasedsalivationandamild

irritationofthestomach.Tiamulinhydrogenfumaratehasarelativelyhigh

therapeuticindexinpigs.Theminimumlethaldosehasnotbeenestablishedinpigs.

Ifsignsofpoisoningareobserved,withdrawrapidlythemedicatedwaterand

replaceitwithfreshwater.Appropriatesymptomatictreatmentshouldbeinitiated.

4.11 Withdrawalperiod(s)

Meatandoffal

5days

5. PHARMACOLOGICALORIMMUNOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Pleuromutilins.

ATCVetCodeQJ01XQ01

5.1 Pharmacodynamicproperties

Tiamulinhydrogenfumarateisasemi-syntheticderivativeofthediterpeneantibiotic

pleuromutilin,producedbyPleurotusmutilis.

Tiamulinisbacteriostaticandinhibitsproteinsynthesis.Theproducthasastrong

affinityfortheribosome,causinganinhibitionofpeptidyltransferases.Asaresult

proteinsynthesisisstopped.

Invitroresearchhasshownthatresistantbacterialmutantscanbecreatedthrough

multistepresistance.Inpractice,resistanceinmycoplasmashasbeenreported

rarely.ResistanceagainstB.hyodysenteriaehasbeenseen,howeverthisspirochete

remainsverysensitivetotiamulin.

Ifresponsetotreatmentofdysenterywiththeproductispoor,thenthepossibilityof

resistancemustbeconsidered.Crossresistancebetweentiamulinandtylosinhas

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

beenreported.

5.2 Pharmacokineticproperties

Followingoraladministration,tiamulinhydrogenfumarateisrapidlyabsorbedfrom

thegastrointestinaltractofpigs(85-90%)andappearsinthebloodwithin30

minutes.2-4hours(t

)aftertheoraladministrationof10mgtiamulin/kgBWinthe

formofanoralsolution,aC

of1µg/mlwasmeasured;anoraladministrationof

25mg/kggaveaC

of1.82µg/ml.

Thereisverygooddistributioninthetissueswithaccumulationinlungsandinthe

colon.30-50%oftiamulinisboundtoserumproteins.

Tiamulinisrapidlymetabolisedintheliver(hydroxylation,de-alkalysation,

hydrolysis).Atleast16biologicallyinactivemetaboliteshavebeenidentified.The

excretionoftiamulinanditsmetabolitesisthroughthebileandfaeces(70-85%).

Theremainderisexcretedthroughtheurine(15-30%).

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Disodiumphosphate,anhydrous

Methylparahydroxybenzoate(E218)

Propylparahydroxybenzoate(E216)

Ethanol96%

Purifiedwater

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale

30months

Shelf-lifeafterfirstopeningtheimmediatepackaging:3months

Shelf-lifeafterdilutionaccordingtodirections:24hours

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

6.4 Specialprecautionsforstorage

Donotstoreabove25°C.

6.5 Natureandcompositionofimmediatepackaging

Vetmulin125mg/mlispresentedina1litrewhitehighdensitypolyethylenebottle

withwhitepolypropylenetamper-evidentclosuresealedwithwhitefoameddisk.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewith

nationalrequirements.

7.1 MARKETINGAUTHORISATIONHOLDER

HuvepharmaNV

Uitbreidingstraat80

2600Antwerpen

Belgium

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10. DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Veterinaryprescription

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

LABEL

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Vetmulin125mg/mlOralSolutionforuseindrinkingwaterforpigs(BE,BG,CZ,EL,HU,IE,

NL,PL,RO,UK,ES,IT,AT,DE,PT)

VetmulinVet,OralSolutionforuseindrinkingwaterforpigs(DK)

Vetmulin101.2mg/mlOralSolutionforuseindrinkingwaterforpigs(FR)

Tiamulinhydrogenfumarate.

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

Activesubstance

Eachmlcontains:125mgTiamulinhydrogenfumarate(equivalentto101.2mgtiamulin)

Excipients

Methylparahydroxybenzoate(e218)

Propylparahydroxybenzoate(e216)

3. PHARMACEUTICALFORM

Oralsolutionforuseindrinkingwater.Clearcolourlesstoslightlyyellowliquid.

4. PACKAGESIZE

1litre

5. TARGETSPECIES

Pigs

6. INDICATION(S)

Seepackageleaflet

7. METHODANDROUTE(S)OFADMINISTRATION

Indrinkingwater

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

Readthepackageleafletbeforeuse.

8. WITHDRAWALPERIOD

Meat&Offal:5days

9. SPECIALWARNING(S),IFNECESSARY

Useoftheproductshouldbebasedonsusceptibilitytestingandtakeintoaccountofficialand

localantimicrobialpolicies

Strategictreatmentshouldbelimitedtoanimalswheretiamulinsusceptibleagentshave

beenisolatedintheherd.Longtermorrepeateduseshouldbeavoidedbyimproving

managementpracticeandthoroughcleansinganddisinfection

Severegrowthdepressionordeathmayresultifanimalsreceiveproductscontaining

monensin,salinomycin,narasin,maduramycinorotherionophoresduringorforatleast

sevendaysbeforeoraftertreatmentwiththeproduct

Usersafetywarnings:

Peoplewithknownhypersensitivitytotheactivesubstancemustnotadministerthe

veterinarymedicinalproduct

Whenmixing,directcontactwiththeskinandmucousmembranesshouldbeavoided.

Accidentalingestionshouldbeavoided.Wearoveralls,safetyglasses,maskandimpervious

gloveswhenhandlingormixingtheproduct.Contaminatedclothingshouldberemovedand

anysplashesontotheskinshouldbewashedoffimmediately.Ifaccidentaleyecontact

occurs,immediatelyrinsethoroughlywithwater.Seekmedicaladviceifirritationpersists.

Washhandsafteruse.

.

10.EXPIRYDATE

<EXP{month/year}>

Onceopened,usewithin3months

Oncediluted,usewithin24hours

Onceopeneduseby:

11.SPECIALSTORAGECONDITIONS

Storebelow25°C.

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

12.SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSOR

WASTEMATERIALS,IFANY

Anyunusedveterinaryproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithnationalrequirements.

13. THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSOR

RESTRICTIONSREGARDINGSUPPLYANDUSE,ifapplicable

Foranimaltreatmentonly

Tobesuppliedonlyonveterinaryprescription

14.THEWORDS “KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keepoutofthereachandsightofchildren.

15.NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

HuvepharmaNV

Uitbreidingstraat80

2600Antwerpen

Belgium

manufacturerresponsibleforbatchreleaseintheEEA.

BiovetJSC,

39PetarRakovStr,

4550Peshtera –Bulgaria

16.MARKETINGAUTHORISATIONNUMBER(S)

17. MANUFACTURER’SBATCHNUMBER

<Batch><Lot><BN>{number}

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

PACKAGELEAFLET

Vetmulin125mg/mlOralSolutionforuseindrinkingwaterforpigs(BE,BG,CZ,EL,HU,IE,

NL,PL,RO,UK,ES,IT,AT,DE,PT)

VetmulinVet,OralSolutionforuseindrinkingwaterforpigs(DK)

Vetmulin101.2mg/mlOralSolutionforuseindrinkingwaterforpigs(FR)

Tiamulinhydrogenfumarate

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERANDOF

THEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFORBATCH

RELEASE,IFDIFFERENT

Marketingauthorisation

HuvepharmaNV,Uitbreidingstraat80,2600Antwerpen,Belgium

Manufacturer

BiovetJSC,39PetarRakovStr,4550Peshtera-Bulgaria

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Vetmulin125mg/mlOralsolutionforuseindrinkingwaterforpigs

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENT(S)

Activesubstance

Eachmlcontains:125mgTiamulinhydrogenfumarate(equivalentto101.2mgtiamulin

Clearcolourlesstoslightlyyellowliquid.

Excipients

Methylparahydroxybenzoate(E218): 0.90mg

Propylparahydroxybenzoate(E216): 0.10mg

4. INDICATION(S)

Forthetreatmentofswinedysenterycausedbyorfurthercomplicatedbytiamulin-

susceptibleBrachyspirahyodysenteriae.

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

Treatmentofenzooticpneumoniaandthereductionoflesionscausedbytiamulin-

susceptibleMycoplasmahyopneumoniae.

5. CONTRAINDICATIONS

Donotuseinanimalswithknownhypersensitivitytotheactiveingredient.

Donotadministerproductscontainingmonensin,salinomycin,narasin,maduramycinor

otherionophoresduringorforatleastsevendaysbeforeoraftertreatmentwiththeproduct.

6. ADVERSEREACTIONS

Inrarecases,hypersensitivitytotiamulinfollowingoraladministrationisreportedintermsof

cutaneousandgenitalerythemaandpruritus.Theadversereactionsareoftenmildand

transientbutinveryrarecasesmaybeserious.Ifthesetypicalsideeffectsoccur,stop

treatmentimmediatelyandcleananimalsandpenswithwater.Normally,theanimalsrecover

fastthereafter.Symptomatictreatmentsuchaselectrolytetherapyandananti-inflammatory

therapymaybeuseful.Ifyounoticeanyseriousorothereffectsnotmentionedinthisleaflet,

pleaseinformyourveterinarysurgeon

7. TARGETSPECIES

Pigs

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOFADMINISTRATION

Swinedysentery

8.8mgtiamulinhydrogenfumarateperkgbodyweightperday(equivalentto7mlproduct

per100kgbodyweightperday)for5consecutivedays.

Enzooticpneumonia

15-20mgtiamulinhydrogenfumarateperkgbodyweightperday(equivalentto12 –

16mlproductper100kgbodyweightperday)for5days.

Administration:

Theuptakeofmedicatedwaterdependsontheactualbodyweight,thewaterconsumption,

theclinicalconditionoftheanimals,theenvironment,theageandthekindoffeedprovided.

Inordertoobtainthecorrectdosage,theconcentrationoftiamulinshouldbecalculated,as

follows:

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

.....mlVetmulin125mg/ml

oralsolutionforusein

drinkingwaterperkgbody

weightandday

x Averagebody

weight(kg)

=....mlVetmulin125mg/mloral

solutionforuseindrinkingwater

perlitreofdrinkingwater

Averagedailywaterintake(l/animal)

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyaspossibleto

avoidunderdosing.Therequireddosesshouldbemeasuredbysuitablycalibrated

measuringequipment.

Medicatedwatershouldberefreshedevery24hours.Theuptakeofconsistentamountsof

drinkingwatershouldbeensuredbysufficientdrinkingfacilities.

Toavoidformationofresistancebyconsumptionoftiamulininsubtherapeuticdoses,the

wateringequipmenthastobecleanedadequatelyattheendoftreatment.

9. ADVICEONCORRECTADMINISTRATION

Theuptakeofmedicationbyanimalscanbealteredasaconsequenceofillness.

Incaseofinsufficientuptakeofwater,animalsshouldbetreatedparenterally’

10.WITHDRAWALPERIOD

Meatandoffal

5days

11.SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Storebelow25°C.

Shelf-lifeafterdilutionaccordingtodirections:24hours

Shelf-lifeafterfirstopeningtheimmediatepackaging:3months

Donotuseaftertheexpirydatestatedonthelabel

12.SPECIALWARNING(S)

Theuptakeofmedicationbyanimalscanbealteredasaconsequenceofillness.

Incaseofinsufficientuptakeofwater,animalsshouldbetreatedparenterally.

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

Useoftheproductshouldbebasedonsusceptibilitytestingandtakeintoaccountofficialand

localantimicrobialpoliciesStrategictreatmentshouldbelimitedtoanimalswheretiamulin

susceptibleagentshavebeenisolatedintheherd.Longtermorrepeateduseshouldbe

avoidedbyimprovingmanagementpracticeandthoroughcleansinganddisinfection

Severegrowthdepressionordeathmayresultifanimalsreceiveproductscontaining

monensin,salinomycin,narasin,maduramysinorotherionophoresduringorforatleast

sevendaysbeforeoraftertreatmentwiththeproduct.

Theproductcanbeusedduringpregnancyandlactation.

Tiamulinmaylessentheantibacterialactivityofß-lactamantibioticswhoseactionis

dependantonbacterialgrowth

Asingleoraldoseof100mg/kgBWcausedhyperpnoeaandabdominalcomplaintsinpigs.

Atadoseof150mg/kgtheonlyeffectsonthecentralnervoussystemwaslethargy.Adose

of55mg/kgduring14dayscausedincreasedsalivationandamildirritationofthestomach.

Tiamulinhydrogenfumaratehasarelativelyhightherapeuticindexinpigs.Theminimum

lethaldosehasnotbeenestablishedinpigs.

Ifsignsofpoisoningareobserved,withdrawrapidlythemedicatedwaterandreplaceitwith

freshwater.Appropriatesymptomatictreatmentshouldbeinitiated

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixed

withotherveterinarymedicinalproducts.

Donotstoreabove25°C.

Usersafetywarnings:

Peoplewithknownhypersensitivitytotheactivesubstancemustnotadministerthe

veterinarymedicinalproduct

Whenmixing,directcontactwiththeskinandmucousmembranesshouldbeavoided.

Accidentalingestionshouldbeavoided.Wearoveralls,safetyglasses,maskandimpervious

gloveswhenhandlingormixingtheproduct.Contaminatedclothingshouldberemovedand

anysplashesontotheskinshouldbewashedoffimmediately.Ifaccidentaleyecontact

occurs,immediatelyrinsethoroughlywithwater.Seekmedicaladviceifirritationpersists.

Washhandsafteruse.

13.SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIALS,IFANY

Anyunusedveterinaryproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithnationalrequirements.

SUMMARYOFPRODUCTCHARACTERISTICS

Vetmulin125mg/mlSolution HuvepharmaNV

14.DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

15.OTHERINFORMATION

Foranyinformationaboutthisveterinarymedicinalproduct,pleasecontactthelocal

representativeofthemarketingauthorisationholder.

Vetmulin125mg/mlispresentedina1litrewhitehighdensitypolyethylenebottlewithwhite

polypropylenetamper-evidentclosuresealedwithwhitefoameddisk.

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Publiekscampagne Ik Zorg van start

Publiekscampagne Ik Zorg van start

Vandaag gaven minister Hugo de Jonge, minister Bruno Bruins en staatssecretaris Paul Blokhuis het startsein voor de publiekscampagne Ik Zorg. Hiermee willen de sector Zorg en Welzijn en de overheid nieuwe werknemers aantrekken. Dat is hard nodig, om ook in de toekomst iedereen goede zorg te kunnen blijven bieden. Als we nu niks doen, hebben we in 2022 een tekort van 125.000 mensen.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

25-6-2018

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approved Epidiolex (cannabidiol) oral solution, the first drug comprised of an active ingredient derived from marijuana, to treat two rare and severe forms of epilepsy.

FDA - U.S. Food and Drug Administration

21-6-2018

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

NOW Health Group, Inc. (NOW), of Bloomingdale, Illinois, is recalling its NOW Real Food® Zesty Sprouting Mix – Product Code 7271, Lot #3031259 and Lot #3038165 – because its primary ingredient, Crimson Clover Seeds, has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may b...

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Active substance: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile) - Orphan designation - Commission Decision (2018)7272 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/18

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

28-5-2018

Seresto and its associated name Foresto

Seresto and its associated name Foresto

Seresto and its associated name Foresto (Active substance: imidacloprid/flumethrin) - Community Referrals - Art 13 - Commission Decision (2018)3404 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/125

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Active substance: Cysteamine bitartrate) - Transfer of orphan designation - Commission Decision (2018)3133 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/164/13/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (Active substance: Single-chain urokinase plasminogen activator) - Transfer of orphan designation - Commission Decision (2018)3150 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/14/T/01

Europe -DG Health and Food Safety